Keyword

dose-finding

Description: Dose-finding is the process of identifying suitable doses of a medicine or intervention, often through clinical trial designs that compare dose levels.

Primary topic: Statistical Methods in Clinical Trials (21%)

Wikidata ID: wiki/Q5299247

OpenAlex ID: keywords/dose-finding

Continual Reassessment Method: A Practical Design for Phase 1 Clinical Trials in Cancer

1990 · John O'Quigley, Margaret Pepe, et al. · Biometrics · 1,577

Subcutaneous Golimumab Induces Clinical Response and Remission in Patients With Moderate-to-Severe Ulcerative Colitis

2013 · William J. Sandborn, Brian G. Feagan, et al. · Gastroenterology · 941

PDF

Clinical Trials : A Methodologic Perspective

1997 · Steven Piantadosi · 800

A Randomized, Double–Blind Trial Comparing Pegylated Interferon Alfa–2B to Interferon Alfa–2B As Initial Treatment for Chronic Hepatitis C

2001 · Karen L. Lindsay, Christian Trepo, et al. · Hepatology · 668

Dose‐Finding Based on Efficacy–Toxicity Trade‐Offs

2004 · Peter F. Thall, John D. Cook · Biometrics · 522

A randomised dose finding study of oral tacrolimus (FK506) therapy in refractory ulcerative colitis

2006 · H Ogata, T Matsui, et al. · Gut · 462

PDF

Isoprostanes: Potential Markers of Oxidant Stress in Atherothrombotic Disease

1997 · Carlo Patrono, Garret A. FitzGerald · Arteriosclerosis Thrombosis and Vascular Biology · 453

PDF

The Safety and Efficacy of Infliximab in Moderate to Severe Chronic Obstructive Pulmonary Disease

2007 · Stephen I. Rennard, Charles Fogarty, et al. · American Journal of Respiratory and Critical Care Medicine · 439

Targeted therapy for high-grade glioma with the TGF- 2 inhibitor trabedersen: results of a randomized and controlled phase IIb study

2010 · U. Bogdahn, P. Hau, et al. · Neuro-Oncology · 433

PDF

Effect of Vericiguat, a Soluble Guanylate Cyclase Stimulator, on Natriuretic Peptide Levels in Patients With Worsening Chronic Heart Failure and Reduced Ejection Fraction

2015 · Mihai Gheorghiade, Stephen J. Greene, et al. · JAMA · 397

PDF

Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study

2018 · Dominique Baeten, Mikkel Østergaard, et al. · Annals of the Rheumatic Diseases · 389

PDF

Continual Reassessment Method: A Likelihood Approach

1996 · John O'Quigley, Larry Z. Shen · Biometrics · 382

Effect of Intra-Articular Sprifermin vs Placebo on Femorotibial Joint Cartilage Thickness in Patients With Osteoarthritis

2019 · Marc C. Hochberg, Ali Guermazi, et al. · JAMA · 350

PDF

Clinical Trial Designs for Cytostatic Agents: Are New Approaches Needed?

2001 · Edward L. Korn, Susan G. Arbuck, et al. · Journal of Clinical Oncology · 331

Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study

2022 · Jonathan P Piccini, Valeria Caso, et al. · The Lancet · 323

PDF

Adaptive Designs in Clinical Drug Development—An Executive Summary of the PhRMA Working Group

2006 · Paul Gallo, Christy Chuang-Stein, et al. · Journal of Biopharmaceutical Statistics · 323

First-in-Human Phase I/IB Dose-Finding Study of Adagrasib (MRTX849) in Patients With Advanced KRAS G12C Solid Tumors (KRYSTAL-1)

2022 · Sai-Hong Ignatius Ou, Pasi A. Jänne, et al. · Journal of Clinical Oncology · 314

Handbook of Design and Analysis of Experiments

2015 · Chapman & Hall/CRC eBooks · 309

Efficacy and safety of secukinumab in patients with rheumatoid arthritis: a phase II, dose-finding, double-blind, randomised, placebo controlled study

2012 · Mark C Genovese, Patrick Durez, et al. · Annals of the Rheumatic Diseases · 293

A double-blind, randomized, dose-finding study to assess the efficacy of the gonadotrophin-releasing hormone antagonist ganirelix (Org 37462) to prevent premature luteinizing hormone surges in women undergoing ovarian stimulation with recombinant follicle stimulating hormone (Puregon). The ganirelix dose-finding study group

1998 · Human Reproduction · 293

Luspatercept for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes (PACE-MDS): a multicentre, open-label phase 2 dose-finding study with long-term extension study

2017 · Uwe Platzbecker, Ulrich Germing, et al. · The Lancet Oncology · 291

Comparable efficacy and safety profiles of once-per-cycle pegfilgrastim and daily injection filgrastim inchemotherapy-induced neutropenia: a multicenterdose-finding study in women with breast cancer

2002 · F.A. Holmes, S.E. Jones, et al. · Annals of Oncology · 291

A Strategy for Dose-Finding and Safety Monitoring Based on Efficacy and Adverse Outcomes in Phase I/II Clinical Trials

1998 · Peter F. Thall, Kathy E. Russell · Biometrics · 278

The effect of dose on the safety and immunogenicity of the VSV Ebola candidate vaccine: a randomised double-blind, placebo-controlled phase 1/2 trial

2015 · Angela Huttner, Julie-Anne Dayer, et al. · The Lancet Infectious Diseases · 272

Safety and immunogenicity of S-Trimer (SCB-2019), a protein subunit vaccine candidate for COVID-19 in healthy adults: a phase 1, randomised, double-blind, placebo-controlled trial

2021 · Peter Richmond, Lara Hatchuel, et al. · The Lancet · 270

PDF

Works count: 3,336

Citation count: 70,290